AllSight
Companies · AMCR · Miscellaneous Manufacturing Industries · Auditor change · Aug 14, 2026

A new auditor, but no accounting alarm bells

Auditor changenew
PwC Switzerland replaced by PwC US effective August 14, 2026
Amcor plc (AMCR) — what happened, in plain English, and what it means versus what the market expected.

This is an auditor transition, not an accounting-warning filing. The board accepted PwC Switzerland’s resignation and appointed PwC US, effective August 14, 2026, because Amcor is now a U.S. domestic reporting company with increasing U.S. operations (Board). 〔0〕

The filing explicitly rules out the red flags that would make an auditor change negative. PwC Switzerland issued no adverse or disclaimed opinions for fiscal 2026 or 2025 (Board). 〔1〕

There were also no disclosed disputes or reportable events. Amcor says it had no disagreements with PwC Switzerland over accounting principles, disclosures, or audit scope, and no reportable events during either fiscal year (Board).

Net read: neutral and operational. With no financial restatement, audit qualification, disagreement, or accounting issue disclosed, the filing is best understood as a structural change in the audit relationship rather than a deterioration in reporting quality. PwC US will begin with the transition fiscal year ending December 31, 2026, including the interim review for the period ending September 30, 2026 (Board).

Read the original 8-K on SEC EDGAR ↗
More from Amcor plc (AMCR)
Aug 12, 2026The Berry deal is paying off—but underlying demand still isn’tJun 15, 2026Planned division-president retirement formalized; transition terms add little new informationAll AMCR filings, decoded →
Related companies in Miscellaneous Manufacturing Industries
Latest across the market
NTSTNETSTREIT debt amendment formalizes investment-grade pricing and widens leverage cushionFLOCFlowco acquisition adds Canadian rod lift but increases debt-funded execution riskCTRECareTrust acquisition adds 45 UK care homes, but SHOP payoff is years awayIARTIntegra earnings: flooding cuts 2026 guidance as Q3 revenue misses consensusSRZNSurrozen FDA clearance unlocks $95.1M financing, but dilution followsCELCCelcuity adds director with big-pharma CFO experience as launch beginsBrowse all companies, decoded →
Open live on AllSight — the whole market, decoded →
AllSight turns SEC filings into plain-English, neutral reads and objective market context. We explain what happened and how it lands versus expectations — we do not give investment advice or predict prices. Decoded straight from the filing; check it against the source.
Analysis by AllSight · Editorial standards & method · Contact